Literature DB >> 21752441

What effect does asthma treatment have on airway remodeling? Current perspectives.

Sheharyar R Durrani1, Ravi K Viswanathan, William W Busse.   

Abstract

Airway remodeling, or structural changes of the airway wall arising from injury and repair, plays an important role in the pathophysiology of asthma. Remodeling is characterized as structural changes involving the composition, content, and organization of many of the cellular and molecular constituents of the bronchial wall. These structural changes can include epithelial injury, subepithelial thickening/fibrosis, airway smooth muscle hyperplasia, goblet cell hypertrophy and hyperplasia, and angiogenesis. Historically, these changes are considered a consequence of long-standing airway inflammation. Recent infant and child studies, however, suggest that remodeling occurs in parallel with inflammation in asthmatic subjects. Despite advancements in the recognition of key cellular and molecular mechanisms involved in remodeling, there remains a paucity of information about which treatments or interactions are most likely to regulate these processes. Furthermore, it is unclear as to when is the best time to initiate treatments to modify remodeling, which components to target, and how best to monitor interventions on remodeling. Indeed, inhaled corticosteroids, which are generally considered to have limited influence on remodeling, have been shown to be beneficial in studies in which the dose and duration of treatment were increased and prolonged, respectively. Moreover, several studies have identified the need to identify novel asthma indices and phenotypes that correlate with remodeling and, as a consequence, might specifically respond to new therapies, such as anti-IgE, anti-IL-5, and anti-TNF-α mAbs. Our review will evaluate the development of remodeling in asthmatic subjects and the effects of treatment on these processes.
Copyright © 2011 American Academy of Allergy, Asthma & Immunology. Published by Mosby, Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21752441     DOI: 10.1016/j.jaci.2011.06.002

Source DB:  PubMed          Journal:  J Allergy Clin Immunol        ISSN: 0091-6749            Impact factor:   10.793


  44 in total

Review 1.  Pathogenetic and prognostic roles of bloodborne fibrocytes in asthma.

Authors:  Sabrina Mattoli
Journal:  J Zhejiang Univ Sci B       Date:  2015-08       Impact factor: 3.066

2.  Semaphorin 3A Is Effective in Reducing Both Inflammation and Angiogenesis in a Mouse Model of Bronchial Asthma.

Authors:  Sabag D Adi; Nasren Eiza; Jacob Bejar; Hila Shefer; Shira Toledano; Ofra Kessler; Gera Neufeld; Elias Toubi; Zahava Vadasz
Journal:  Front Immunol       Date:  2019-03-22       Impact factor: 7.561

Review 3.  Effects of exercise training on airway hyperreactivity in asthma: a systematic review and meta-analysis.

Authors:  Philipp A Eichenberger; Stephanie N Diener; Reto Kofmehl; Christina M Spengler
Journal:  Sports Med       Date:  2013-11       Impact factor: 11.136

Review 4.  Putting the Squeeze on Airway Epithelia.

Authors:  Jin-Ah Park; Jeffrey J Fredberg; Jeffrey M Drazen
Journal:  Physiology (Bethesda)       Date:  2015-07

Review 5.  Collective migration and cell jamming in asthma, cancer and development.

Authors:  Jin-Ah Park; Lior Atia; Jennifer A Mitchel; Jeffrey J Fredberg; James P Butler
Journal:  J Cell Sci       Date:  2016-08-22       Impact factor: 5.285

6.  The tyrosine kinase inhibitor dasatinib reduces lung inflammation and remodelling in experimental allergic asthma.

Authors:  A L da Silva; R F Magalhães; V C Branco; J D Silva; F F Cruz; P S Marques; T P T Ferreira; M M Morales; M A Martins; P C Olsen; P R M Rocco
Journal:  Br J Pharmacol       Date:  2016-02-25       Impact factor: 8.739

7.  AVE 0991, a non-peptide mimic of angiotensin-(1-7) effects, attenuates pulmonary remodelling in a model of chronic asthma.

Authors:  M G Rodrigues-Machado; G S Magalhães; J A Cardoso; L M Kangussu; A Murari; M V Caliari; M L Oliveira; D C Cara; M L M Noviello; F D Marques; J M Pereira; R Q Lautner; R A S Santos; M J Campagnole-Santos
Journal:  Br J Pharmacol       Date:  2013-10       Impact factor: 8.739

8.  DNA nanoparticle-mediated thymulin gene therapy prevents airway remodeling in experimental allergic asthma.

Authors:  Adriana L da Silva; Sabrina V Martini; Soraia C Abreu; Cynthia dos S Samary; Bruno L Diaz; Sandra Fernezlian; Vanessa Karen de Sá; Vera Luiza Capelozzi; Nicholas J Boylan; Rodolfo Gustavo Goya; Jung Soo Suk; Patricia R M Rocco; Justin Hanes; Marcelo M Morales
Journal:  J Control Release       Date:  2014-02-17       Impact factor: 9.776

9.  Soy isoflavones reduce asthma exacerbation in asthmatic patients with high PAI-1-producing genotypes.

Authors:  Seong H Cho; Ara Jo; Thomas Casale; Su J Jeong; Seung-Jae Hong; Joong K Cho; Janet T Holbrook; Rajesh Kumar; Lewis J Smith
Journal:  J Allergy Clin Immunol       Date:  2019-01-29       Impact factor: 10.793

10.  Postnatal overnutrition in mice leads to impaired pulmonary mechanics in response to salbutamol.

Authors:  Vanessa P Teixeira; Daniela A B Cervilha; Layla D M Cabral; Luiz M Oliveira; Erika K Incerpi; Rômulo D Novaes; Marisa Ionta; Roseli Soncini
Journal:  J Physiol Sci       Date:  2015-10-23       Impact factor: 2.781

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.